Track topics on Twitter Track topics that are important to you
The purpose of this study is to evaluate the absolute oral bioavailability (how fast and how much study drug is absorbed in the body) of a single 300-mg oral dose of canagliflozin in healthy male volunteers.
This is an open-label (the patient will know the identity of the treatment they receive), single-dose, single-center study to evaluate the absolute oral bioavailability (the rate and extent at which the drug is absorbed in the body and reaches blood circulation) of a 300-mg tablet of canagliflozin. Approximately 9 healthy men (referred to as healthy male volunteers) will receive a single 300-mg tablet of canagliflozin with an 8 ounce glass of water followed 105 minutes later by a 15 minute intravenous (iv) infusion (administration directly in the vein) of a very small dose (ie, 10 micrograms [mcg]) of canagliflozin that has been combined with a radioactive carbon isotope referred to as 14C canagliflozin. The radiolabelled 10 mcg dose of canagliflozin will act as a tracer to measure the total amount of canagliflozin that is absorbed and metabolized in the body. After dosing, blood, urine and feces samples will be collected for pharmacokinetic and safety evaluations at specified timepoints for up to 72 hours. The primary outcome measure in the study is to determine the absolute bioavailability of a single 300 mg dose of canagliflozin by estimation of protocol-specified standard plasma pharmacokinetic parameters (parameters that measure the absorption, distribution, metabolism, and elimination of drug by the body) from blood samples obtained during the study. During the study, the safety of a single oral 300-mg dose of canagliflozin administered together with a single iv 10-mcg infusion dose of 14C-canagliflozin will be evaluated by monitoring adverse events and findings from clinical laboratory test values, physical examination results, 12 lead ECGs and vital signs measurements reported. On Day 1, each healthy volunteer will take a single 300-mg canagliflozin tablet orally (by mouth) with 8 ounces of water in the morning followed by a 15-minute intravenous infusion of 10 mcg 14C-canagliflozin (200 nCi) (equivalent to 0.666 mcg/mL of canagliflozin). Healthy volunteers will fast at least 10 hours before dosing and until at least 4 hours after oral administration and will not be allowed to drink water from 2 hours before and up to 4 hours after study drug administration.
Endpoint Classification: Bio-availability Study, Intervention Model: Single Group Assignment, Masking: Open Label
Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
Published on BioPortfolio: 2014-08-27T03:12:25-0400
The purpose of this study is to evaluate the efficacy, safety, and tolerability of 2 different doses of canagliflozin administered as monotherapy compared with placebo in patients with typ...
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin XR Tablet Co-administered With Canagliflozin in Healthy Fed and Fasted Participa
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet co-ad...
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release (XR) With Respect to Metformin XR Tablet Coadministered With Canagliflozin in Healthy Fed and Fasted Parti
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablets co-a...
A Study to Assess the Bioequivalence of the Metformin Component of the Fixed Dose Combination Tablet of Canagliflozin and Metformin Extended Release With Respect to Metformin Extended Release Tablet Coadministered With Canagliflozin in Healthy Fed and Fas
The purpose of this study is to evaluate bioequivalence of the metformin component of the Fixed Dose Combination (FDC) tablet compared with the metformin Extended Release (XR) tablet coadm...
The study will assess canagliflozin (JNJ-28431754) in the treatment of patients with type 2 diabetes mellitus (T2DM) with regard to cardiovascular (CV) risk for major adverse cardiac even...
Recently Khouri et al performed a disproportionality analysis of the WHO database of individual case safety reports, suggesting that amputations from use of SGLT2-inhibitors could be a class effect, o...
Elevated blood glucose and insulin resistance are triggering factors for non-alcoholic steatohepatitis (NASH). We investigated the effects of the Sodium Glucose co-Transporter 2 (SGLT2) inhibitor cana...
Type 2 diabetes and obesity are pro-inflammatory states associated with increased risk of cardiovascular disease. Canagliflozin, an SGLT2 inhibitor, demonstrated superiority in lowering HbA1c versus g...
Albuminuria characterizes the progression of kidney injury. The effect of canagliflozin on the excretion of microalbumin was assessed for investigating its renoprotective potential in Japanese patient...
Efficacy and safety of replacing sitagliptin with canagliflozin in real-world patients with type 2 diabetes uncontrolled with sitagliptin combined with metformin and/or gliclazide: The SITA-CANA Switch Study.
To analyze the efficacy and safety of replacing sitagliptin with canagliflozin in patients with type 2 diabetes (T2D) and poor metabolic control despite treatment with sitagliptin in combination with ...
Healthy People Programs are a set of health objectives to be used by governments, communities, professional organizations, and others to help develop programs to improve health. It builds on initiatives pursued over the past two decades beginning with the 1979 Surgeon General's Report, Healthy People, Healthy People 2000: National Health Promotion and Disease Prevention Objectives, and Healthy People 2010. These established national health objectives and served as the basis for the development of state and community plans. These are administered by the Office of Disease Prevention and Health Promotion (ODPHP). Similar programs are conducted by other national governments.
A glucoside-derived SODIUM-GLUCOSE TRANSPORTER 2 inhibitor that stimulates urinary excretion of glucose by suppressing renal glucose reabsorption. It is used to manage BLOOD GLUCOSE levels in patients with TYPE 2 DIABETES.
Governmental guidelines and objectives pertaining to public food supply and nutrition including recommendations for healthy diet and changes in food habits to ensure healthy diet.
Surgical reinnervation of a denervated peripheral target using a healthy donor nerve and/or its proximal stump. The direct connection is usually made to a healthy postlesional distal portion of a non-functioning nerve or implanted directly into denervated muscle or insensitive skin. Nerve sprouts will grow from the transferred nerve into the denervated elements and establish contact between them and the neurons that formerly controlled another area.
Dietary patterns which have been found to be important in reducing disease risk.
Pharmacy is the science and technique of preparing as well as dispensing drugs and medicines. It is a health profession that links health sciences with chemical sciences and aims to ensure the safe and effective use of pharmaceutical drugs. The scope of...
Within medicine, nutrition (the study of food and the effect of its components on the body) has many different roles. Appropriate nutrition can help prevent certain diseases, or treat others. In critically ill patients, artificial feeding by tubes need t...